Yesterday, the biotechnology company Capstan Therapeutics launched with $165 million in seed and Series A funding for it to build on its foundational insights into precision in vivo engineering ...

June 30 (Reuters) - AbbVie (ABBV.N), opens new tab said on Monday it would acquire privately held cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 billion, expanding its product ...

AbbVie has agreed to acquire Capstan Therapeutics for up to $2.1bn, adding a “high-risk, high-reward” clinical-stage in vivo CAR-T candidate to its pipeline. Capstan is developing a new type of CAR-T ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

When it comes to legged robots, it’s easy to think that the complexity and machining costs would keep these creatures far away from becoming anyone’s garage hobby. But, through a series of clever ...

Aaed Musa] has been building robot dogs for a long time now, so it was only natural that he would make one for the senior design project of his mechanical engineering degree. Since this meant ...

AbbVie is making a full strength play for the in vivo CAR-T market, snapping up Capstan Therapeutics for $2.1 billion to add an early-phase autoimmune drug candidate to its pipeline. Capstan is part ...

AbbVie wasn’t part of the first wave of cell therapies developed for cancer, but it is positioning itself to contend in the next one, which is expanding to therapies made by engineering immune cells ...

SAN DIEGO--(BUSINESS WIRE)--Capstan Therapeutics, Inc. (“Capstan”), a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery utilizing targeted lipid ...

SAN DIEGO & PHILADELPHIA--(BUSINESS WIRE)--Capstan Therapeutics, Inc., a biotechnology company dedicated to developing and delivering precise in vivo cell engineering to patients, launched today with ...

University of Pennsylvania scientists who pioneered advances in cell therapy and messenger RNA have unveiled a new venture aiming to bring cell-based therapies into a new frontier: the engineering of ...